Pexidartinib and standard neoadjuvant therapy in the adaptively randomized i-spy2 trial for early breast cancer
HIGHLIGHTS What: Instead, the authors provide a summary of response rates and event-free survival (EFS) of pexidartinib-treated patients. Given the […]